Specifically, NF-κB has been shown to confer resistance to bortezomib (BTZ) through a BM-MSC-secreted IL-8-dependent stimulation pathway or via its activation by an autophagy-related mechanism [31,32]; this explains in part the effectiveness of NF-κB inhibitors in MM. Here, NFKB1 is linked to Miyoshi myopathy.